Story perspectives

Free Genomic Testing Revolutionizes Rare Cancer Treatment for Kids

9/5/2025

31 5

Summary

Story summary

Memorial Sloan Kettering Cancer Center's Make-an-IMPACT program offers no-cost genomic testing for pediatric patients with rare cancers.
MSK-IMPACT testing provided new diagnostic information to 41% of solid tumor and 38% of CNS tumor patients.
The anti-CD40 antibody 2141-V11 showed safety and effectiveness, with two patients achieving complete tumor disappearance.
Dupilumab resolved skin toxicities from antibody-drug conjugates in 73% of treated patients.
SUMO2 inhibition shows potential for targeted therapies in synovial sarcoma, which has limited treatment options.

1 of 1

Story summary

Memorial Sloan Kettering Cancer Center's Make-an-IMPACT program offers no-cost genomic testing for pediatric patients with rare cancers.
MSK-IMPACT testing provided new diagnostic information to 41% of solid tumor and 38% of CNS tumor patients.
The anti-CD40 antibody 2141-V11 showed safety and effectiveness, with two patients achieving complete tumor disappearance.
Dupilumab resolved skin toxicities from antibody-drug conjugates in 73% of treated patients.
SUMO2 inhibition shows potential for targeted therapies in synovial sarcoma, which has limited treatment options.